Overview

Durvalumab Combined With Chemoradiotherapy for Limited Stage Small Cell Lung Cancer (Camel-01)

Status:
RECRUITING
Trial end date:
2027-12-31
Target enrollment:
Participant gender:
Summary
This trial aims to assess efficacy and safety of durvalumab combined with chemoradiotherapy for limited stage small cell lung cancer.
Phase:
PHASE2
Details
Lead Sponsor:
Hebei Medical University Fourth Hospital
Treatments:
durvalumab
Radiotherapy